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QUANTITATIVE T1 MAPPING IN CARDIOMYOPATHY 
OWEN MACLEOD HENDRY 
ABSTRACT 
  
 Recent advancements in techniques of Cardiac Magnetic Resonance Imaging 
provide extended quantitative measurements of myocardial T1.  Important tissue 
characteristics can be tracked noninvasively to allow practitioners to quantify important 
properties of regional and global myocardium function.  Quantification of these T1 
measures involves the compilation of multiple images to create a T1 recovery curve, 
providing a map that estimates the T1 value as an encoded pixel value. After contrast 
injection, the data is compared with native (no applied contrast agent) T1 to examine 
myocardial disease involving the interstitium as well as the extracellular volume fraction. 
Myocardial T1 mapping is an emerging biomarker for quantification of myocardial 
disease (since an important indicator of heart disease is the expansion of myocardial 
interstitial space, as is fibrosis).  
 This paper explores the detection and quantification of cardiac involvement using 
delayed gadolinium enhancement combined with T1 mapping and myocardial 
extracellular volume fraction.  It extends the research being conducted on Cardiac 
sarcoidosis, an important cardiomyopathy.  Cardiac sarcoidosis is a multisystem 
granulomatous disease of unknown etiology.  Cardiac MR is able to detect the active, 
inflammatory phase of the disease as well as the chronic phase where scarring and 
fibrosis are dominant.  The use of gadolinium-based contrast agents improves the ability 
  vii 
to discriminate ischemic from nonischemic etiologies, owing to different patterns among 
the various nonischemic cardiomyopathies.  Since gadolinium shortens T1 relaxation 
time, the result is a brighter signal intensity in areas with increased interstitial space on 
inversion recovery T1-weighted sequences.   
 The 1.5 Tesla Philips Achieva XR Scanner was used to collect the pre- and post- 
contrast images from five anonymous patients (subjects), following the MOLLI protocol.  
These images were stacked and run through MRMap, which creates parametric image 
maps of the MOLLI data. Data was graphed employing the Gado Partition Coefficient.   
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INTRODUCTION 
 
 Cardiovascular disease (CVD) is a class of diseases involving the heart and 
circulatory system.  CVD is the leading threat to human health within the United States 
and Western World.  The American Heart Association estimates that 80 million people in 
the United States have one or more forms of CVD.  As the epidemic of obesity, diabetes, 
and hypertension grows, 40.5% of the US population is projected to have some form of 
CVD by 2030.  [12]  
 Cardiovascular disease includes many specific illnesses such as coronary heart 
disease, heart failure, cardiomyopathies, arrhythmias, stroke, pulmonary and arterial 
hypertension, valvular heart disease, congenital heart disease, and rheumatic heart 
disease.  Because of the wide array of illness associated with CVD, it is important to 
determine accurately and noninvasively cardiac function in order to diagnose and treat 
heart disease.  [12] Magnetic resonance imaging (MRI) is a quickly evolving modality 
that provides noninvasive assessment of cardiac function, morphology, tissue 
characterization, and perfusion for patients.   
 The definition of cardiomyopathies has been evolving as diagnostic technology 
changes and improves.  The cardiomyopathies were formerly classified according to the 
anatomy and physiology into the following types: dilated cardiomyopathy (DMC), 
hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), 
arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), and unclassified 
cardiomyopathy. [2,5]    The current definition and classification of cardiomyopathies 
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was proposed by the American Heart Association (AHA) in 2006.  The AHA defined it 
as "cardiomyopathies are a heterogeneous group of diseases of the myocardium 
associated with mechanical and/or electrical dysfunction that usually (but not invariably) 
exhibit inappropriate ventricular hypertrophy or dilation and are due to a variety of 
causes that frequently are genetic.  Cardiomyopathies either are confined to the heart or 
are part of generalized systemic disorders, often leading to cardiovascular death or 
progressive heart failure related disability."  [3]  
 Cardiomyopathies are classified into two groups.  Primary cardiomyopathies 
mostly involve the heart and secondary cardiomyopathies are accompanied by other 
organ system involvement.  It is important to establish the exact etiology for correct 
treatment.  Cardiovascular MRI (CMR) is a rapidly evolving technology that has seen 
huge growth in the use of noninvasive imaging of the heart.  Its ability to characterize the 
myocardial and valvular structures and function makes it essential in the diagnostic 
process and therapeutic management.  [2]  
(1.1) Magnetic Resonance  
 Magnetic resonance is a dynamic technology that allows for an imaging study of 
the anatomic part of interest and the disease process being studied. A magnetic resonance 
imaging (MRI) system is made up of three main electromagnetic components: a set of 
main magnet coils, three gradient coils and an integral radiofrequency transmitter coil.  
Each coil generates a separate type of magnetic field which, when applied to the patient, 
together create spatially encoded magnetic resonance signals that are used to form MR 
images. The three different types of magnetic field are defined as follows. 
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 A strong, constant magnetic field is generated by the main magnet coils. [11] The 
patient is positioned for imaging within the central bore of the magnet, where the strength 
of this field, Bo, defines the operating field strength of the particular MRI system. Bo is 
measured in units of Tesla, (T) with 1 Tesla equal to approximately 20,000 times the 
earth's magnetic field. The most common field strength for cardiac imaging today is 1.5T. 
A reference coordinate system of three orthogonal axes, x, y and z is used to define the 
magnetic field direction, with the z axis chosen to be parallel to the direction of Bo. [11] 
 A gradient magnetic field is generated by the three gradient coils within the main 
magnet.  These can be rapidly switched on and off.   Each of these gradient coils 
generates a magnetic field in the same direction as Bo but with a strength that changes 
with position along the x, y or z directions, depending on which gradient coil is used. 
This gradient field is superimposed onto the Bo magnetic field so that its strength 
increases (or decreases) along the direction of the applied gradient field. The strength of 
the gradient magnetic field reflects the 'steepness' of its slope and is measured in units of 
millitesla per meter (mT/m). [11]  
 A radiofrequency (rf) magnetic field is generated by the rf transmitter coil from 
within the gradient coil.  It has a much smaller amplitude than the other magnetic fields, 
but oscillates at a characteristic frequency in the megahertz range (hence, 
radiofrequency), the value of which is determined by the nominal field strength of the 
main magnet. The rf field is often referred to as the B1 field. The static magnetic field and 
radiofrequency field combine to generate magnetic resonance signals that are spatially 
localized and encoded by the gradient magnetic fields to create an MR image. For cardiac 
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imaging, a separate rf receiver coil placed directly over the chest that is tailored to 
maximize signal from the heart is normally used to detect the emitted MR signals. [11] 
(1.12) Generating the MR signal 
 The chemical origin of the MR signal used to generate images is either from water 
or fat within the patient's tissue.  More specifically, it comes from the hydrogen nuclei 
made up of a single proton, and water/fat are the most abundant species in living tissue.  
Contained within free water or lipid molecules, Hydrogen is one of a number of elements 
whose nuclei exhibit magnetic resonance properties and its natural abundance in the form 
of water and lipid molecules makes it particularly favorable for imaging. [9]  The 
Hydrogen nuclei possess an essential property known as nuclear spin that gives rise to a 
small magnetic field for each proton, known as a magnetic moment. [11] Normally the 
magnetic moments (spins) are randomly oriented, but with an externally applied Bo field, 
they tend to align either toward or against the externally applied magnetic field.  An 
equilibrium state is quickly attained where there is a small excess of spins aligned with 
the field.  This is the more energetically favorable direction of alignment. The excess of 
proton magnetic moments combines to form a net magnetic field or net magnetization. 
This is often given the symbol M and at equilibrium it is aligned along the positive z axis 
(along Bo) with the value, Mo. It is often shown as an arrow or vector.  [11] 
 The size of this net magnetization is one of the key determinants of the maximum 
signal intensity that can be generated and used to form images. The greater the applied 
magnetic field strength, Bo, the greater the excess of protons aligned with the magnetic 
field and the greater the size of the net magnetization. [11]  
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In order to generate a MR signal from the net magnetization, the radiofrequency (rf) 
magnetic field is generated by the integral rf transmitter coil and used to deliver energy to 
the population of protons. This field is applied at a particular frequency, known as the 
Larmor frequency, ωo that is determined by the Larmor equation: 
ωo=γ × Bo 
The constant γ is called the gyromagnetic ratio and has a value of 42.6 MHz/Tesla for the 
proton. The Larmor frequency is proportional to the strength of the magnetic field and for 
1.5 Tesla, the Larmor frequency is approximately 64 MHz. [11] This is also known as the 
resonance frequency, as the protons only absorb energy (or resonate) at this characteristic 
frequency. The rf field is normally applied as a short pulse, known as an rf pulse. [9]  
 
(1.13) Radiofrequency pulses and flip angle 
Before the rf pulse is activated, the net magnetization, Mo, is at equilibrium.  It is aligned 
along the z-axis in the same direction as Bo  and rapidly rotates When the rf pulse is 
switched on, the net magnetization starts to rotate away from the Bo field. The speed of 
this rotational motion, known as precession, is also at the Larmor frequency. The 
movement of the net magnetization away from alignment with Bo is caused by a much 
slower rotation around the smaller applied rf field, B1. This oscillating field, B1 is applied 
as a rotating field at right angles to Bo in the plane of the x and y axes. [11] As it rotates at 
the same frequency as the Larmor frequency, it appears as an additional static field to the 
rotating net magnetization vector. The net magnetization therefore rotates around both the 
Bo and the B1 fields. As a result of these two rotations, the net magnetization follows a 
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spiral path from its alignment with the Bo field (z-axis) towards a rotational motion in the 
plane of the x and y axes. [11] 
Net magnetization is the result of the sum of many individual magnetic moments.  As the 
magnetic moments rotate together, they will produce a net magnetization that is rotating 
as well.  The greater the amount of energy applied by the rf pulse, the greater the angle 
that the net magnetization moves from the Bo field (the z axis). [9] This depends upon 
both the amplitude and duration of the pulse. The rf pulse is switched off once the angle 
of precession has reached a desired value. This is known as the flip angle of the rf pulse. 
Once the rf pulse has caused the net magnetization to make an angle with the z-axis, it 
can be split into two parts. One section is parallel to the z-axis and is known as the z-
component of the magnetization, Mz, also known as the longitudinal component. The 
other component lies at right angles to the z axis within the plane of the x and y axes and 
is known as the x-y component of the net magnetization, Mxy, or the transverse 
component.  [9] The transverse component rotates at the Larmor frequency within the xy 
plane and as it rotates, it generates its own small, oscillating magnetic field which is 
detected as an MR signal by the rf receiver coil.  [11] 
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Figure 1: T1 relaxation process [11]  
 
Figure 1 illustrates the process of T1 relaxation after a 90° rf pulse is applied at 
equilibrium. The z component of the net magnetization, Mz is reduced to zero, but then 
recovers gradually back to its equilibrium value if no further rf pulses are applied.  
 
 Excitation pulses are radiofrequency pulses that generate an MR signal by 
delivering energy to the hydrogen population, causing the magnetization to move away 
from equilibrium. A 90° rf excitation pulse delivers just enough energy to rotate the net 
magnetization through 90° [9] This transfers all of the net magnetization from the z-axis 
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into the xy (transverse) plane, leaving no magnetization along the z-axis immediately 
after the pulse. The system of protons is then said to be 'saturated'.  [11]  When applied 
once, a 90° rf pulse produces the largest possible transverse magnetization and MR 
signal. 
 The 180° pulse refocuses and is used after the 90° excitation pulse, where the net 
magnetization has already been transferred into the x-y plane. It flips the direction of the 
magnetization in the x-y plane through 180° as it rotates at the Larmor frequency. This 
pulse is used in spin echo-based techniques to reverse the loss of coherence caused by 
magnetic field in homogeneities. [11] The 180° pulses are also used to prepare the net 
magnetization before the application of an excitation pulse. These are known as inversion 
pulses and are used in inversion recovery or dark-blood pulse sequences. [11]   
(1.2) T1 and T2 relaxation  
 Immediately after the rf pulse, the system begins to return to equilibrium. This is 
known as relaxation. There are two relaxation processes that relate to the two components 
of the Net Magnetization, the longitudinal (z) and transverse (xy) components. 
Longitudinal relaxation, known as T1 relaxation is responsible for the recovery of the z 
component along the longitudinal (z) axis to its original value at equilibrium.  [4,7] The 
second relaxation process, transverse relaxation (T2), is responsible for the decay of the 
xy component as it rotates about the z axis, causing a subsequent decay of the MR signal. 
Longitudinal and transverse relaxation both occur at the same time, however, transverse 
relaxation is typically a much faster process for human tissue. [11]  
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(1.21) Causes of T1 Relaxation  
 T1 is also known as spin-lattice relaxation time and describes how quickly the 
longitudinal magnetization recovers to its equilibrium.  Re-growth of longitudinal 
relaxation requires a net transfer of energy from the nuclear spin system to its 
environment (“lattice”) [16]. Because T1 relaxation requires an energy switch, and  
because all MR energy exchanges must be stimulated, T1 relaxation only can occur when 
a proton encounters another magnetic field fluctuating near the Larmor frequency. [16] 
The source of this fluctuating field is usually another proton or electron, and the 
interaction is known as a dipole-dipole interaction. [16] In order for a proton or electron 
to produce a fluctuating magnetic field to cause the T1 relaxation, the molecule in which 
it resides must be tumbling. The molecule must be rotating near the Larmor frequency to 
cause T1 relaxation well. Thus, the tumbling rate of the molecule can affect the T1 
relaxation time significantly. Small molecules like water tumble too quickly to cause 
effective T1 relaxation. However, when the water is in a partially bound or restricted 
state, as it is briefly bonded to proteins and other macromolecules, its tumbling rate may 
be slowed to a speed near the Larmor frequency. This makes the T1 value of free water 
very long and the “bound” water is much shorter [16].  
 The magnetic field strength affects the T1 of different molecules in a different 
way. For protons in highly mobile molecules (such as free water), the T1 value changes 
very little because the fraction of protons precessing at Larmor frequency is not altered 
appreciably. For protons in molecules with intermediate or low mobility, the T1 will 
 10 
increase at higher field strength as the fraction of protons decreased significantly at 
higher Larmor frequency.  [3,10] 
 
(1.22) Importance of the T1 value 
 T1 relaxation is an exponential process with a time constant T1. The shorter the 
T1 time constant, the faster the relaxation process and return to equilibrium. Recovery of 
the z-magnetization after a 90° rf pulse is known as saturation recovery.  T1 relaxation 
involves the release of energy from the proton spin population as it returns to its 
equilibrium state. [11] The rate of relaxation is related to the rate at which energy is 
released to the surrounding molecular structure. This in turn is related to the size of the 
molecule that contains the hydrogen nuclei and in particular the rate of molecular motion, 
known as the tumbling rate of the particular molecule. As molecules tumble or rotate they 
give rise to a fluctuating magnetic field which is experienced by protons in adjacent 
molecules. When this fluctuating magnetic field is close to the Larmor frequency, energy 
exchange is more favorable. Lipid molecules are of a size that gives rise to a tumbling 
rate which is close to the Larmor frequency and therefore extremely favorable for energy 
exchange. Fat therefore has one of the fastest relaxation rates of all body tissues and 
therefore the shortest T1 relaxation time. Larger molecules have much slower tumbling 
rates that are unfavorable for energy exchange, giving rise to long relaxation times. For 
free water, its smaller molecular size has a much faster molecular tumbling rate which is 
also unfavorable for energy exchange and therefore it has a long T1 relaxation time. The 
tumbling rates of water molecules that are adjacent to large macromolecules can however 
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be slowed down towards the Larmor frequency, shortening the T1 value. Water based 
tissues with a high macromolecular content like muscle therefore tend to have shorter T1 
values. Conversely, when the water content is increased, for example by an inflammatory 
process, the T1 value also increases. 
Figure 2: Approximate T1 and T2 tissue relaxation values at 1.5T [12] 
 
 
(1.23) T2 relaxation  
 Transverse relaxation (T2) is the result of the sum of the magnetic moments of an 
entire population of protons within tissues. The presence of interactions between 
neighboring protons causes a loss of phase coherence known as T2 relaxation.  [11] 
Immediately after the rf pulse, they rotate together, so that as they rotate they constantly 
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point in the same direction within the xy plane. [11] The angle of the direction they point 
at any time is known as the phase angle and the spins with similar phase angles are in 
phase.  Over time, the phase angles gradually spread out, there is a loss of coherence and 
the magnetic moments no longer rotate together.  The net sum of the magnetic moments 
is thus reduced, resulting in a reduction in the measured net (transverse) magnetization. 
The signal that the receiver coil detects if no more rf pulses or magnetic field gradients 
are applied is therefore seen as an oscillating magnetic field that gradually decays called 
Free Induction Decay (FID). [11]. 
 
(1.3) Cardiac Magnetic Resonance Imaging  
 Cardiac magnetic resonance (CMR) is evolving into the imaging modality of 
choice for differentiating the etiology of cardiomyopathies.  In comparison to other 
imaging modalities such as X-ray fluoroscopy, computed tomography, and ultrasound, 
MRI provides excellent spatial resolution and soft tissue contrast without radiation 
exposure.  [10,16]  By using different pulse sequences and acquisition parameters, MRI 
allows us to examine myocardial function, morphology, perfusion, valvular function, 
myocardial tissue characterization and so on.  Given its enhanced spatial resolution, 
improved tissue characterization, and lack of ionizing radiation, MRI has become the best 
choice in the evaluation of patients with cardiomyopathy of unknown etiology.  The use 
of gadolinium based contrast agents can further improve the ability of MRI to 
discriminate ischemic from non ischemic etiologies owing to different hyper 
enhancement patterns among the various non ischemic cardiomyopathies. [10,16]  
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 Delayed enhancement (DE) MRI (also termed late gadolinium enhancement or 
hyper-enhancement) defines areas of myocardial fibrosis by imaging 10–15 minutes after 
gadolinium contrast is administered to the patient.  Delayed gadolinium retention in the 
interstitial space is increased in conditions with increased extracellular volume of 
distribution and/or decreased washout such as acute necrosis, fibrosis, infiltration and 
inflammation [10]. Since gadolinium shortens T1 relaxation time, the result is a brighter 
signal intensity in the areas with increased interstitial space on inversion recovery T1- 
weighted sequences [3,10].  The presence of delayed enhancement is not specific for any 
cardiomyopathy though. It is the pattern and location of enhancement that helps in 
diagnosis and differentiates the diverse etiologies of cardiomyopathies. [3,10] 
 
(1.31) Extracellular Volume Fraction 
 With the addition of a contrast agent, the extracellular volume (ECV) can be 
estimated.  This is a direct measure of the extracellular space, reflecting interstitial 
disease.  This attempts to split the myocardium into its cellular and interstitial 
components with estimates expressed as volume fractions. [10,16]  The purpose is to 
evaluate a change in T1 before and after the administration of contrast agent.  It is 
measured as the percent of tissue comprised of extracellular space which is independent 
of field strength.  [10,16]  The ECV in the myocardium may be estimated from the 
concentration of extracellular contrast agent in the myocardium relative to the blood in a 
dynamic steady state.   
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(1.4) Physics of T1 Mapping Techniques  
Spin-lattice Relaxation Time  
 Used in the clinical setting, MRI exploits the magnetic property of hydrogen 
protons in the human body for diagnostic purposes. The term “spin” comes from the 
quantum mechanical description of MRI. In 1946, Felix Bloch described nuclear MR 
phenomenon [16]. Bloch assumed that the ensemble of spins  could be represented as a 
net nuclear magnetization (M) behaving according to the laws of classical 
electromagnetism. If the spins constituting M interact only with the external magnetic 
field (B), they will experience a torque given by the vector cross product (M×B) [16]. 
Because the torque of a system is equal to the time rate of change of its angular 
momentum, Bloch presented the motion of M could be a simple precession around B by 
the equation:  
dM / dt = M × γ B + M0 − Mz/T1 - Mxy/T2 
 If the spins interact with each other and their environment, M will not precess 
indefinitely around B, but will return to its original alignment with the main magnetic 
field (B) with the equilibrium magnitude M0. To return back to the equilibrium state, the 
spin system must release its energy to the environment, which was termed as relaxation 
by Bloch. [16] Two time constants T1 and T2 were introduced by Bloch to account for 
the reestablishment of the thermal equilibrium of the nuclear magnetization following an 
RF pulse. T1 relaxation was assumed following first-order kinetics by Bloch.  
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(1.5) Gold standard biomarkers  
(1.51) T1 Mapping  
 T1 mapping is a cardiac magnetic resonance method that provides a parametric 
map in which the T1 value is encoded in each individual pixel.  T1 maps result from a 
series of co-registered images taken at different times of T1 recovery.  Myocardial T1 
mapping is an emerging biomarker for quantification of myocardial disease.  A major 
indicator of heart disease is the expansion of myocardial interstitial space, usually 
through the development of fibrosis.  [3]   New developments in cardiovascular magnetic 
resonance in the measurement of the myocardial T1 relaxation time and the extracellular 
volume (ECV) have the potential to provide a new biomarker in diagnosis of cardiac 
disease.  T1 relaxation time is a magnetic timing parameter depending on the surrounding 
molecular environment of tissue and the local magnetic field.  [10] 
 
(1.52) Native (noncontrast) T1 
 Native T1 refers to the longitudinal relaxation time (T1) values of a given tissue 
with no applied contrast agent.  Native T1 measures of myocardium allow for 
noninvasive detection of biologically important processes which can be used to improve 
diagnosis, measures of disease severity, and potentially prognosis.  [10,16]  Native T1 
changes indicate the presence of disease due to increased water content or other changes 
to the local molecular environment.  [7] Iron or fat in tissue reduces native T1 while with 
fibrosis, edema, and amyloidosis native T1 increases.  [11]   
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(1.53) T1 Mapping with “Look Locker” Inversion Recovery (LL)  
 Many cardiac pulse sequences have been developed for T1 mapping, which are 
used to characterize diseased myocardial tissue.  The Look Locker method was 
developed in 1970 to accelerate the data acquisition process. To calculate T1 more 
quickly, the inversion recovery curve was sampled multiple times after a single inversion 
rather than once as in the conventional inversion recovery-spin echo acquisition. The LL 
method uses a series of small flip angle excitation pulses (7-15°)  after an inversion pulse 
to sample the inversion recovery curve with different inversion times. [16]  The time 
interval between inversion pulses must be long enough to allow magnetization to return 
to equilibrium.  
 Although LL is highly useful, it has inaccuracies resulting from the low flip angle 
RF pulses exciting the magnetization intermittently.  This causes them to fail to return to 
equilibrium magnetization before the next inversion pulse, often making the T1 values 
underestimated. [16]  Because the images are acquired continuously throughout the 
cardiac cycle, there is a strong possibility of cardiac motion.  Thus, a region of interest 
(ROI) is required, drawn in an area of the myocardium and moved along with the cardiac 
motion to calculate T1 in a focal area/lesion of the myocardium.  [15,16]    
 
(1.54) T1 Mapping with Modified Look Locker Inversion Recovery (MOLLI)  
 MOLLI was developed in 2004 and is a variant of Look Locker. It is a technique 
that uses electrocardiogram-gated image acquisition at end-diastole and merges images 
from multiple consecutive inversion-recovery experiments into one single data set.  
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[10,16]  The traditional MOLLI protocol uses three inversion-recovery blocks to acquire 
11 images over 17 heartbeats.  This may present an issue with patients who have 
weakened respiratory function due to cardiac diseases because of the requirement for 
long breath holds.   [10] 
(1.6)  Cardiomyopathies 
Myocardial fibrosis 
 Myocardial fibrosis is characterized by expansion of the myocardial extracellular 
matrix.  Accumulation of interstitial collagen is the main characteristic of pathologic 
remodeling.  This derangement affects electrical and mechanical function. [13] 
Extracellular collagen, the primary component of the expanded extracellular matrix, 
blocks electrical conduction, is a major component of lethal ventricular arrhythmia, and 
hardens the myocardium.  While CMR with delayed gadolinium enhancement can 
distinguish large amounts myocardial fibrosis, it cannot detect the full spectrum of 
myocardial fibrosis.   [15]  
(1.61) Ischemic Cardiomyopathy 
 Ischemic cardiomyopathy is defined as dysfunction of the left ventricle as a result 
of chronic lack of oxygen due to coronary artery disease.  [16] With coronary artery 
disease, myocardial ischemia may result in hibernation,  stunning, and true infarction. 
Stunned myocardium occurs after an acute ischemic event causing reversible contractile 
dysfunction.  Hibernation refers to chronic contractile impairment secondary to chronic 
hypoperfusion, where the myocardium is still viable. [15,16] By either percutaneous 
coronary intervention or coronary artery bypass grafting, viable tissue can be 
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revascularized and therefore myocardial contractility of the viable tissue can be 
improved.  [15,16] 
On delayed contrast enhanced T1-weighted images, infarcted tissues appear bright owing 
to retained contrast in the region of infarct with decreased contractile ability apparent on 
the corresponding cine images. On DE MR images, infarcted myocardium and fibrosis 
appear as high signal intensity in an area of coronary artery distribution. Since all 
infarctions start subendocardially and may progress towards epicardium, the 
subendocardium is always involved. [1,16] 
 
(1.62) Hypertrophic Cardiomyopathy  
  Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease in which 
the myocardium becomes abnormally thick or hypertrophied.  It is a genetic disorder and 
is caused by a variety of mutations in genes encoding contractile proteins of the cardiac 
sarcomere.  [16]  There are currently 11 mutant genes associated with HCM, most 
commonly β-myosin heavy chain and myosin-binding protein C.  [12]  Normal 
ventricular septal thickness is around 8-12 mm and in HCM, the diastolic left ventricular 
wall thickness is 15 mm or more.  [13]  In HCM, the left ventricular volume can be 
reduced or normal and diastolic dysfunction is usually seen.  Premature death and 
arrhythmias are often seen in HCM.   
 Delayed contrast enhanced T1-weighted images typically show patchy, multifocal 
hyper enhancement in patients with HCM occurring only within hypertrophied areas.  It 
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is considered that the patchy enhancement is due to the occurrence of abundant 
connective tissue within the hypertrophic myocardium [15].  
(1.63) Dilated Cardiomyopathy  
  Dilated cardiomyopathy (DCM) is described by ventricular chamber enlargement 
and impaired function of the left ventricle with a left ventricular ejection fraction less 
than 40% [13]. The causes of dilated cardiomyopathy is broad and may be idiopathic, 
familial/genetic, viral and/or immune, alcoholic/toxic.  [16]. DCM leads to progressive 
heart failure and a decline in left ventricular contractile function, arrhythmias, conduction 
system abnormalities, and sudden death.  [16]  DCM is a common and largely irreversible 
form of heart muscle disease.  Patients with idiopathic dilated cardiomyopathy show 
either linear midmyocardial enhancement or no enhancement[10,13]. This enhancement 
is thought to be due to fibrosis.  
(1.64) Cardiac sarcoidosis 
 Sarcoidosis is defined by the American Thoracic Society as a multisystem 
granulomatous  disease of unknown etiology.  A significant contributor of disease 
development and progression is the individually defined immune response and degree of 
inflammation, which represents a major target for diagnosis and therapy.  Lymph nodes 
and lungs are most frequently involved, but the disease can affect any other organ and 
cardiac involvement commonly occurs.  Cardiac involvement leads to varied outcomes 
and ranges from asymptomatic to sudden cardiac death.  Cardiac sarcoidosis is 
determined by the severity of the disease and the location.  [3]  The most frequently 
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involved area is the ventricular septum (31.5%), followed by the inferior wall, anterior 
left ventricle, right ventricle, and lateral left ventricle.  [12]  
 Cardiac MR is able to detect the active, inflammatory phase of the disease as well 
as the chronic phase where scarring and fibrosis are predominant.  [12] The active phase 
is distinguished by focal wall thickening due to edema (identified by T2-weighted 
imaging) with wall motion abnormalities seen on cine images and early gadolinium 
enhancement noted due to excessive capillary leak.  The chronic stage mostly shows wall 
thinning with delayed gadolinium enhancement, representing myocardial damage, 
scarring, and fibrosis.  [12]  The two phases often overlap.   
 The objective of this study is to utilized advanced T1 studies such as  MOLLI and 
ECV to assess cardiac function in patients with known cardiomyopathy with a focus on 
cardiac sarcoidosis.   
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Table 1:  Proposed diagnostic and therapeutic strategy for cardiac sarcoidosis [12]  
Indications for screening 
 Diagnosed extracardiac sarcoidosis 
 Unexplained persisting second- or 
third-degree atrioventricular block 
and age < 55 y 
 Unexplained monomorphic 
ventricular tachycardia 
 Nonischemic dilated 
cardiomyopathy 
 Routine screening procedures Findings leading to further work-up 
Clinical symptoms, physical 
examination 
 
12-lead electrocardiogram 
Bundle branch block, ventricular ectopy, second- 
or third-degree atrioventricular block (atrial 
arrhythmia, first-degree atrioventricular block) 
Echocardiogram 
Global LV dysfunction, regional wall motion 
abnormalities (right ventricular dysfunction) 
Holter monitoring 
Runs of ventricular tachycardia, nonsustained 
ventricular tachycardia (frequent isolated 
premature ventricular contractions) 
Further work-up Findings leading to therapy 
CMR 
Delayed hyperenhancement (LV dysfunction, 
perfusion defects) 
PET 
Patchy or focal 
18
F-FDG uptake (patchy on diffuse 
uptake) 
Invasive electrophysiologic study Abnormal result 
Therapy Triggered by 
Immunomodulation (prednisone 
[30–40 mg]; methotrexate Positive further work-up 
Implantable cardioverter-
defibrillator Positive electrophysiologic study 
Response evaluation Evidence of efficacy improvement 
Symptoms 
 CMR (no implantable cardioverter-
defibrillator) Reduction in T2 signal 
PET Reduction in FDG uptake 
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METHODS  
 The study was approved by the IRB and is HIPPA compliant.  The subjects were 
scanned on a 1.5 Tesla Philips Achieva XR scanner and afterwards had their images 
anonymized.  The sequences used in the optimized cardiac sarcoidosis MOLLI protocol:  
1. T1-BB axial (aortic arch to inferior aspect of heart below diaphragm) 
2.Horitzonal long axis (SSFP cine) 
3. Vertical long axis (SSFP cine) 
4. Short axis stack (SSFP cine) 
5. 4-chamber stack (SSFP cine) 
6. Aortic valve flow 
7. Pulmonic valve flow 
8. T2-BB in short axis plane with STIR 
9. Pre contrast MOLLI 3,3,5 sequence for native T1 map in 3 slices 
10. Standard delayed gadolinium enhancement  
11.  Post contrast (>15 min after injection), MOLLI 3,3,5 in same slices as above) 
 
 Prior to scanning the patient, a blood draw is done to assess their hematocrit level, 
a test that measures the percentage of red blood cells in blood.   Normal range for 
hematocrit is different between the sexes and is approximately 45% to 52% for men and 
37% to 48% for women.  [14]  
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Table 2: Comparison of typical MOLLI sequence parameters [2] 
Sequence Optimized MOLLI sequence Original MOLLI sequence 
Preparation 
Non-selective inversion 
recovery 
Non-selective inversion 
recovery 
Bandwidth 1090 Hz/px 1090 Hz/px 
Flip Angle 35° 50° 
Base Matrix 192 240 
Phase resolution 128 151 
FOX x %phase 256x100 380 x 342 
Inversion Time (TI) 100 ms 100 ms 
Slice Thickness 8 mm 8 mm 
Acquisition window 202 ms 191.1 ms 
Trigger delay 300 ms 300 ms 
Inversions 3 3 
Acquisition 
heartbeats 3,3,5 3,3,5 
Recovery heartbeats 3,3,1 3,3,1 
TI increment 80 ms 100-150 ms 
Scan time 17 heartbeats 17 heartbeats 
Spatial resolution 2.1 x 1.8 x 8 mm 2.26 x 1.58 x 8 mm 
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Figure 3: Subject #4 MOLLI Pre-contrast T1 weighted images (1-8)  
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Figure 4: Subject #4 MOLLI Post contrast T1 weighted images (1-8) 
 
  
  
 
Gadolinium is hand injected at 1ml/second and is based on the patients weight.  Dosage 
increases 1 mL per every 10 kilograms but is 1.5x the usual dose in cardiac studies.   The 
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pre and post contrast images are then stacked and run through MRMap which is a 
program that creates parametric image maps of the MOLLI data.  From there color tables 
are added to the images based on T1 values in milliseconds.   
 
T1 Maps:   
 
Figure 5: Subject #4 Pre contrast grey scale image from MRMap 
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Figure 6: Subject #4 Post Contast grey scale from MRMap 
 
 
 
The T1 map is then imported to ImageJ where a region of interest is drawn free hand 
through the myocardium and within the ventricular blood pool to get T1 values.  
Figure 7: Subject #4 Region of interest drawn through myocardium for T1 value  
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Figure 8: Subject #4 Region of interest drawn in blood for T1 value of blood 
 
 
The T1 value is then converted into R1 or 1/T1 which is the longitudinal relaxation rate 
for both pre and post contrast images of the myocardium and blood.  The R1 values are 
then placed on a scatter chart with the Y-axis utilizing the myocardium pre and post 
contrast values and the X-axis using the blood pre and post contrast values to find the 
slope.  The correction factor is calculated by the equation 1-(Hematocrit/100).  The ECV 
is then measured by multiplying the correction factor by the slope attained in the graph.   
Figure 9:  ECV measurement equation [6] 
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RESULTS 
 
Table 3: Sarcoidosis Subject #1  
 
Pre-Myo Pre-Blood Post-Myo 1 Post-blood 1 
T1 (milliseconds) 983.101 1562.481 303.924 180.42 
R1 (1/T1) 0.00102 0.00064 0.00329 0.00554 
     Y-axis R1 myo 0.00102 0.00329 
  X-axis R1 blood 0.00064 0.00554 
   
HCT (%) Correction factor Slope  
 
ECVF 
47.2 0.528 
 
0.4637 
 
0.24 
 
 
Figure 10: Gado Partition Coefficient Plot Sarcoidosis Subject #1 
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Table and graph for individual subjects listing the T1 values of pre and post contrast 
myocardium and blood.   R1 values listed below the T1 values after calculating (1/T1) for 
each.  The pre and post contrast R1 of myocardium was plotted on the Y-axis while the 
R1 pre and post contrast of blood was plotted along the X-axis.  The slope was derived 
from the graph.  The hematocrit percentage was recorded prior to scanning by a blood 
draw.  Correction factor was measured by 1- (hematocrit / 100).  ECV was then 
calculated by multiplying the slope by correction factor.  Process completed for all other 
subjects. 
Table 4: Sarcoidosis Subject #2 
 
Pre-Myo Pre-Blood Post-Myo 1 Post-blood 1 
T1 (milliseconds) 996.34 1581.454 343.594 182.28 
R1 (1/T1) 0.00100 0.00063 0.00291 0.01 
     Y-axis R1 myo 0.00100 0.00291 
  X-axis R1 blood 0.00063 0.00549 
   
HCT (%) Correction factor Slope  
 
ECVF 
  1 
 
0.4783 
 
0.48 
 
 
 
Figure 11: Gado Partition Coefficient Plot Sarcoidosis Subject #2 
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Table 5: Sarcoidosis Subject #3 
 
 
Pre-Myo Pre-Blood Post-Myo 1 Post-blood 1 
T1 (milliseconds) 1032.659 1651.6 371.334 215.97 
R1 (1/T1) 0.000968 0.000605 0.002693 0.004630 
     Y-axis R1 myo 0.000968 0.002693 
  X-axis R1 blood 0.000605 0.004630 
   
HCT (%) Correction factor Slope  
 
ECVF 
27.8 0.722 
 
0.4285 
 
0.31 
 
 
 
 
Figure 12: Gado Partition Coefficient Plot Sarcoidosis Subject #3 
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Table 6: Sarcoidosis Subject #4 
 
Pre-Myo Pre-Blood Post-Myo 1 Post-blood 1 
T1 (milliseconds) 972.262 1522.378 480.651 234.911 
R1 (1/T1) 0.00103 0.00066 0.00208 0.00426 
 
HCT (%) Correction factor Slope  
 
ECVF 
42.5 0.575 
 
0.2922 
 
0.17 
 
 
 
 
 
Figure 13: Gado Partition Coefficient Plot Sarcoidosis Subject #4 
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Table 7:  Sarcoidosis Subject #5 
 
 
Pre-Myo Pre-Blood Post-Myo 1 Post-blood 1 
T1 (milliseconds) 999.316 1522.153 477.124 246.84 
R1 (1/T1) 0.00100 0.00066 0.00210 0.00405 
     Y-axis R1 myo 0.00100 0.00210 
  X-axis R1 blood 0.00066 0.00405 
   
HCT (%) Correction factor Slope  
 
ECVF 
34.6 0.654 
 
0.3227 
 
0.21 
 
 
Figure 14: Gado Partition Coefficient Plot Sarcoidosis Subject #5 
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Table 8:  Other T1 values from subjects (tissues within field of view) 
 
Subject #1 T1 values (ms) Liver Fat 
 
Pre contrast 461 273 
 
Post Contrast 295 282 
Subject #2 
 
Liver Fat 
 
Pre contrast 508 229 
 
Post Contrast 303 251 
Subject #3 
 
Liver Fat 
 
Pre contrast 522 308 
 
Post Contrast 280 277 
Subject #4 
 
Liver Fat 
 
Pre contrast 592 283 
 
Post Contrast 202 294 
Subject #5 
 
Liver Fat 
 
Pre contrast 567 309 
 
Post Contrast 230 359 
 
 
T1 values of liver and fat measured from the images processed as a reference to cardiac 
T1 values.  The approximate T1 value at 1.5T for liver is 500 and for fat is 250.  Most 
values fall within this range and slight deviation may be due to artifact affecting the 
selected ROI mean. 
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Table 9: Pre and post contrast T1 statistical analysis 
 
  
Pre contrast 
myo 
Post contrast 
Myo 
Pre contrast 
blood 
Post contrast 
blood 
Patient #1 
 
983.101 303.924 1562.481 180.42 
Patient #2 
 
996.34 343.594 1581.454 182.28 
Patient #3 
 
1032.659 371.334 1651.6 215.97 
Patient #4 
 
972.262 480.651 1522.378 234.911 
Patient #5 
 
999.316 477.124 1522.153 246.84 
 
Mean 996.736 395.325 1568.013 212.084 
 
SD 22.815 79.965 53.347 30.146 
 
 
An organized data table collecting all T1 values for pre and post contrast myocardium 
and blood of all five subjects.  Averages were taken of each column and the standard 
deviation was found for each to evaluate statistical differences among the patients.   
 
Figure 15: Subject #1 Pre and post contrast MOLLI T1 map   
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Pre and post contrast MOLLI T1 maps post processed with MRMap for each subject.  
Color added using blue/green/red/yellow color table based off the T1 ms reference range 
along the left side.   
 
 
Figure 16: Subject #2 Pre and post contrast MOLLI T1 map 
 
 
 
 
 
Figure 17: Subject #3 Pre and post contrast MOLLI T1 map 
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Figure 18: Subject#4 Pre and post contrast MOLLI T1 map 
 
 
 
 
 
 
Figure 19: Subject #5 Pre and post contrast MOLLI T1 map 
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Table 10: ECV statistical analysis  
  
ECV values 
    Patient #1 0.24 
 
Mean ECV 0.282 
Patient #2 0.48 
 
SD 0.122 
Patient #3 0.31 
   Patient #4 0.17 
   Patient #5 0.21 
    
 
Collection of EVC values of all five patients after calculated by multiplying the slope 
by the correction factor, with the average ECV and standard deviation recorded.   
 
 
 
 
 
 
 
DISCUSSION 
 The objective of this study was to utilize advanced T1 studies to assess cardiac 
function in patients with known cardiomyopathy, with a focus on cardiac sarcoidosis.  In 
general, the normal 'healthy' ECV value ranges from 0.27-0.30 while the average pre 
contrast myocardium T1 values fall around 950-1000 ms.  Using the data obtained from 
this study, the average of the five subjects' ECV was found to be 0.282 with a standard 
deviation of 0.122.  This high standard deviation was to be expected with a low number 
of subjects.  One subject was well above the normal range, three well below, and one 
within the range, all previously diagnosed with cardiac sarcoidosis.   The native T1 
myocardium mean was 996.736 with a standard deviation of 22.815 while the post 
contrast T1 myocardium mean was 395.325 with a standard deviation of 79.965.  The 
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native T1 values fell within the correct range.  The liver T1 values all decreased after 
Gadolinium injection while fat T1 mostly stayed the same.   
 As native T1/post contrast mapping and ECV techniques continue to improve, 
clinicians will be able to develop further insight into cardiac disease processes that are 
difficult to evaluate.  Recent studies indicate that the occurrence of sarcoidosis and the 
risk of mortality relating to cardiac involvement have been on the rise over the past 
several decades. [12] Cardiac sarcoidosis, although an uncommon disease, should be 
considered in all cases of unexplained cardiomyopathy, especially within younger 
patients.   With the emergence of advanced cardiac imaging, CS is being diagnosed 
earlier and more frequently than before.   
 A major limitation to this study was a limited amount of cardiac sarcoidosis 
patients.  Another limitation is the difficult process of reducing cardiac and respiratory 
motion artifact.   In addition to motion artifact, patients with weakened respiratory 
function may have a difficult time holding their breath long enough during acquisitions.  
Luckily, patients rarely have adverse effects to the use of Gadolinium which is a requisite 
of CMR.  This procedure can be quite lengthy (45-60 minutes), requiring the patient to 
remain still longer than many other studies.  The partnership of the radiologist and 
cardiologist is important in determining the extent and pattern of the disease.   The 
information provided through this current research, while somewhat limited to five 
samples, lends strong support for further exploration of noninvasive diagnostic and 
prognostic evaluation of this pathology. 
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